Atoltivimab Explained

Type:	mab
Mab Type:	mab
Source:	u
Target:	Zaire ebolavirus glycoprotein
Pronounce:	a" tol tiv' i mab
Dailymedid:	Atoltivimab
Pregnancy Us:	N
Class:	Monoclonal antibody
Atc Prefix:	None
Cas Number:	2135632-29-8
Unii:	FJZ07Q63VY
Kegg:	D11468
C:	6448
H:	9954
N:	1726
O:	2002
S:	44

Atoltivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus).^{[1] [2] [3]}

External links

• Web site: Atoltivimab . U.S. National Library of Medicine . Drug Information Portal .
• Web site: Statement on a nonproprietary name adopted by the USAN Council USAN (FG-87) Atoltivimab .

Notes and References

1. FDA Approves First Treatment for Ebola Virus . U.S. Food and Drug Administration (FDA) . 14 October 2020 . 14 October 2020.
2. Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus) . Regeneron Pharmaceuticals Inc. . 14 October 2020 . 14 October 2020.
3. Saxena D, Kaul G, Dasgupta A, Chopra S . Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus . Drugs of Today . 57 . 8 . 483–490 . August 2021 . 34405205 . 10.1358/dot.2021.57.8.3280599 . 237198823 .